CLINICAL TRIALS PROFILE FOR VERQUVO
✉ Email this page to a colleague
All Clinical Trials for verquvo
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05420012 ↗ | The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation | Not yet recruiting | Merck Sharp & Dohme LLC | Phase 4 | 2022-08-01 | The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, the aim of the proposed study is to examine the effect of Vericiguat on peripheral vascular function, inflammatory status, and patient health status. The study also aims to identify patients who are particularly likely to benefit from Vericiguat treatment and predict that these patients will be defined by baseline peripheral vascular dysfunction and high inflammatory state. |
| NCT05420012 ↗ | The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation | Not yet recruiting | Josef Stehlik | Phase 4 | 2022-08-01 | The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, the aim of the proposed study is to examine the effect of Vericiguat on peripheral vascular function, inflammatory status, and patient health status. The study also aims to identify patients who are particularly likely to benefit from Vericiguat treatment and predict that these patients will be defined by baseline peripheral vascular dysfunction and high inflammatory state. |
| NCT05711719 ↗ | Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction | Not yet recruiting | Merck Sharp & Dohme LLC | Phase 2 | 2023-03-21 | Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging. |
| NCT05711719 ↗ | Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction | Not yet recruiting | Johns Hopkins University | Phase 2 | 2023-03-21 | Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for verquvo
Condition Name
Clinical Trial Locations for verquvo
Trials by Country
Clinical Trial Progress for verquvo
Clinical Trial Phase
Clinical Trial Sponsors for verquvo
Sponsor Name
